GlobeNewswire

Sciaky Posts Record December with the Sale of Four EBAM® Metal 3D Printing Systems

Dela

The EBAM systems will be used to 3D print titanium structures for aerospace applications, as well as to produce large parts for ground-based military vehicles, and warships

 

CHICAGO, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Sciaky, Inc., a subsidiary of Phillips Service Industries, Inc. (PSI) and leading provider of metal additive manufacturing (AM) solutions, announced today that it has posted record machine sales in the month of December with the sale of four state-of-the-art Electron Beam Additive Manufacturing (EBAM®) systems. The buyers will use the machines to 3D print titanium structures for aerospace applications, as well as to produce large parts for ground-based military vehicles, and warships. Three of the four machines will be the popular EBAM 110 model. The fourth machine will be an EBAM 150 model, which has a nominal part envelope of 146" (3708 mm) x 62" (1575 mm) x 62" (1575 mm), allowing the customer to 3D print the industry's largest metal parts in-house. All four systems will be delivered around mid-2018.    

"Sciaky is proud to deliver more best-in-class EBAM metal 3D printing systems to the marketplace, which will be leveraged in a wide range of land, sea, air and space applications," said Scott Phillips, President & CEO of Sciaky, Inc. "Now, more than ever, manufacturers are looking for ways to reduce time and cost associated with producing large, high-value parts, and Sciaky EBAM systems have a proven track record of helping manufacturers achieve these business-critical goals."

Bob Phillips, Sciaky's Vice President of Marketing, added, "January is shaping up to be another great month for EBAM machine sales, and there will be more exciting industry news coming from Sciaky in the near future."

As the most widely scalable, metal additive manufacturing solution in the industry (in terms of work envelope), Sciaky's EBAM systems produce parts ranging from 8 inches (203 mm) to 19 feet (5.79 meters) in length. EBAM is also the fastest deposition process in the metal additive manufacturing market, with gross deposition rates up to 20 lbs. (9.07 kg) of metal per hour. EBAM brings quality and control together with IRISS® - the Interlayer Real-time Imaging and Sensing System, which is the only real-time monitoring and control system in the metal 3D printing market that can sense and digitally self-adjust metal deposition with precision and repeatability. This innovative closed-loop control is the primary reason that Sciaky's EBAM 3D printing process delivers consistent part geometry, mechanical properties, microstructure, and metal chemistry, from the first part to the last.

For more information on Sciaky, visit www.sciaky.com. You can also follow Sciaky on TwitterFacebookGoogle+YouTube and LinkedIn.

About Sciaky, Inc.

Sciaky, Inc., a subsidiary of Phillips Service Industries, is a world leader in metal 3D printing solutions. Our exclusive Electron Beam Additive Manufacturing (EBAM®) process is the fastest, most cost-effective 3D printing process in the market for large-scale metal parts, allowing manufacturers to save significant time and money over traditional manufacturing and rapid prototyping processes. Sciaky also provides industry-leading electron beam (EB) and advanced arc welding systems, as well as the most robust EB job shop welding services in the world, for the aerospace, defense, automotive, healthcare and other manufacturing industries. Our welding equipment meets rigid military specifications to manufacture items such as airframes, landing gear, jet engines, guided missiles and vehicle parts.

About Phillips Service Industries, Inc.

Established in 1967, Phillips Service Industries, Inc. (PSI) is a privately held global manufacturing and services holding company, which oversees a diverse collection of innovative subsidiaries: Beaver Aerospace & Defense, Inc., Mountain Secure Systems, POWERTHRU, PSI Repair Services, Inc., PSI Semicon Services, and Sciaky, Inc. We serve a wide range of high-tech industries like aerospace, defense, automotive, alternative energy, healthcare, security and semiconductor. Our award-winning products and services help reduce costs and maximize efficiency for many Fortune 500 companies around the globe, as well as the U.S. Military. We push the boundaries of technology on critical programs like Homeland Security, Defense research and space exploration, delivering innovative solutions for land, sea, air and space. We're PSI: Always innovating. Everywhere.(TM)

 

CONTACT:
Jay Hollingsworth
Public Relations Director
Phillips Service Industries (PSI)
(734) 853-5211
jay.hollingsworth@psi-corp.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7ba945f2-ac88-4501-a9ad-ce96d53dc36a




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Phillips Service Industries, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum